Nature2y
Advancing cancer treatment: Targeting the MDM2–p53 interaction in the clinic
2 Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria. 3 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States. The authors would like to thank Jane Saunders of Ashfield ...